Literature DB >> 34661711

Clinical presentation and treatment outcomes of arterial involvement in Behçet's disease: a single-centre experience.

Arghya Chattopadhyay1, Siddharth Jain1, G S R S N K Naidu1, Varun Dhir1, Bharath Chhabria2, Nupoor Acharya1, Valliappan Muthu2, Manphool Singhal3, Ajay Savlania4, Rajesh Vijayvergiya5, Sanjay Jain1, Aman Sharma6.   

Abstract

Arterial involvement, although rare, accounts for significant mortality and morbidity in patients of Behçet's disease (BD). There is paucity of data on arterial BD. The objective of this 5-year retrospective cohort study was to examine the clinical presentation, pattern of arterial involvement, and treatment outcome in Indian arterial BD patients. Data on demography, clinical presentation, radiology, instituted therapy, vascular interventions and treatment outcomes were recorded and analyzed. Ten (16.9%) out of 59 patients with BD had arterial involvement in 13 vascular territories [mean age 30 (8) years, 9 (90%) males]. Pulmonary artery was most commonly involved (46%), followed by abdominal aorta (15%), femoral artery (15%), descending thoracic aorta (8%), common iliac (8%), and dorsalis pedis artery (8%). Two patients had multi-territory involvement. The median interval between disease onset and development of arterial aneurysms was 3 years (3 months-12 years). Concomitant deep vein thrombosis was seen in 60% cases. Prednisolone and cyclophosphamide were the most common immunosuppressive therapy used; one patient who relapsed on cyclophosphamide responded to infliximab. Five surgical or endovascular interventions were performed. Four patients (40%) died due to aneurysm rupture-all had a delayed diagnosis, and three had pulmonary artery involvement, with death due to massive hemoptysis. Based on the present study, we concluded that arterial involvement in BD is seen predominantly in males and has a high mortality. Early detection and aggressive treatment with immunosuppression and surgical or endovascular interventions are essential for good outcomes.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Angio-Behçet; Arterial involvement; Behçet syndrome; Vasculitis

Mesh:

Substances:

Year:  2021        PMID: 34661711     DOI: 10.1007/s00296-021-05022-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  2 in total

1.  2018 update of the EULAR recommendations for the management of Behçet's syndrome.

Authors:  Gulen Hatemi; Robin Christensen; Dongsik Bang; Bahram Bodaghi; Aykut Ferhat Celik; Farida Fortune; Julien Gaudric; Ahmet Gul; Ina Kötter; Pietro Leccese; Alfred Mahr; Robert Moots; Yesim Ozguler; Jutta Richter; David Saadoun; Carlo Salvarani; Francesco Scuderi; Petros P Sfikakis; Aksel Siva; Miles Stanford; Ilknur Tugal-Tutkun; Richard West; Sebahattin Yurdakul; Ignazio Olivieri; Hasan Yazici
Journal:  Ann Rheum Dis       Date:  2018-04-06       Impact factor: 19.103

2.  History and development of Behçet's disease.

Authors:  N Dilsen
Journal:  Rev Rhum Engl Ed       Date:  1996 Jul-Sep
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.